Key facts
- Qymune’s last known valuation is $22.8M (Sep 2025).
- It has raised $11.3M; the latest was Seed Round ($11.0M) in Sep 2025.
- Notable investors include Mirae Asset Capital, AJU IB Investment, Daewoong Pharmaceutical Company, Nextrans, Primer (South Korea) — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Qymune
- ·The full record, as it builds
Funding rounds
No funding rounds for Qymune are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Qymune
Developer of T cell engager therapies designed to deliver full therapeutic efficacy without compromising patient safety. The company's immunotherapy platform utilizes targeted antibody engineering, immune modulation, and controlled activation to redefine human healthcare, enabling patients and medical professionals to access highly effective and fundamentally safe immunological treatments.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 7
- Website
- qymune.com/
- Ownership
- Privately Held (backing)
Qymune doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qymune shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qymune in its N-PORT filings yet. We sweep new filings monthly.